Join us in-person in Boston, MA, USA at SLAS2026. Learn more about our involvement in the event below.
Evotec at SLAS2026
Presentation
High Throughput Transcriptomics for Drug Screening: An Unbiased Multidimensional Readout to Assess Efficacy, Mechanism of Action and Safety Right from the Start
Date and Time: Monday 9th February 2026; 4:00 pm
Presenter: Rüdiger Fritsch, VP Panomics
ScreenSeq™ is a proprietary, scalable 384-well transcriptomics platform designed to enhance early drug discovery by providing an unbiased, multidimensional readout of compound efficacy, safety, and mechanism of action. With over 3 million transcriptomes profiled, it enables high-quality, cost-effective screening from primary hits to hit expansion and SAR analysis. In a study of 20,000 compounds, ScreenSeq™ successfully identified hits that reversed disease-associated transcriptomic signatures, supporting informed decision-making throughout the pipeline. Future work aims to extend its use into lead optimization, creating a fully transcriptomics-enabled workflow from screening to candidate nomination.
